Amplia: FAK Inhibition Animation

Hinzugefügt: 2026-05-28

[00:00:00]Amplia develops next generation FAK inhibitors designed to improve cancer treatment.

[00:00:07]Pancreatic cancer is challenging to treat. It is often diagnosed late when disease has already progressed and long-term survival remains rare.

[00:00:17]Hidden deep within the body, a pancreatic tumor contains many different cells. The body's own support cells, fibrolasts, produce a dense fibrous network that gradually encloses the tumor.

[00:00:29]Chemotherapy relies on drugs reaching all cancer cells throughout the tumor.

[00:00:34]In pancreatic cancer, this is especially difficult because the tumor is tightly wrapped in the dense fibrotic network.

[00:00:41]As a result, chemotherapy achieves only imperfect tumor penetration and is only partially effective.

[00:00:49]Inside the tumor, cancer cells and fibroblasts use a protein called focal adhesion kynise or FAK to support tumor growth and strengthen the surrounding fibrous network.

[00:01:01]Amplia's drug namapotib passes through the fibrous network and blocks the FAK protein inside fibroblasts.

[00:01:09]The ongoing production of the fibrous network is disrupted.

[00:01:13]Namapotinib can also enter cancer cells and kill them directly.

[00:01:18]Without FAK activity, fibroblasts stop producing fibers and the dense network surrounding the tumor begins to disappear.

[00:01:27]With the tumor now exposed, chemotherapy can penetrate more effectively and kill cancer cells. The tumor starts to shrink.

[00:01:37]Napotinib has shown promising efficacy, durability, and tolerability in the phase 2A accent clinical trial in pancreatic cancer. Adding napotinib to chemotherapy appears superior to chemotherapy alone.

[00:01:52]Amplia Therapeutics enhancing cancer treatment.